YSpace Markham Business Venture Lactiga Receives FDA 'Rare Pediatric Disease' Designation for Groundbreaking Mucosal Immunoglobulin Therapy for Common Variable Immunodeficiency Disease

Aug 14, 2023

Lactiga US, Inc., a visionary biotechnology company unlocking the therapeutic value of human milk antibodies, proudly announced today that the US Food and Drug Administration (USFDA) has granted "Rare Pediatric Disease" (RPD) designation for its biologic, LCTG-001, a mucosal antibody replacement therapy comprised of polyclonal Immunoglobulin A (IgA) for nasal administration in patients with Common Variable Immunodeficiency (CVID). This significant milestone represents a major step forward in Lactiga's mission to transform the management of rare and life-threatening immunodeficiencies, especially in pediatric patients.

Full Article: Yahoo Finance